<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>9 Hepatic and biliary tumours</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part14.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part16.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="#bookmark14" class="s95" name="bookmark49">Chapter 9</a><a name="bookmark50">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_125.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark14" class="h2">Hepatic and biliary </a><h2 href="#bookmark14">tumours</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;line-height: 109%;text-align: left;">Marika reinius, edmund godfrey, and Bristi Basu</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 12pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Hepatobiliary tumours account for the largest increase in cancer-specific mortality worldwide. They are broadly categorized by cell type and site of origin: hepatocytes (hepatocellular carcinoma (HCC)), bile duct (cholangiocarcinoma (CCA)), mixed HCC-CCA, and gallbladder carcinoma.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.1.1 <span class="s29">Differential diagnosis</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Imaging facilitates differentiation between benign and primary malignant lesions of the hepatobiliary system (Tables 9.1 and 9.2). The liver is the most common site of metastasis from tumours that drain initially via the portal circulation and in around 25% of cases of colorectal cancers, is a unique site of metastasis. However, other pri- mary solid tumours, for example breast and lung cancers frequently disseminate here.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">9.2 <span class="h4">Diagnosis and staging</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.2.1 <span class="s29">Hepatocellular carcinoma</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.2.1.1 <span class="s98">Background and anatomy</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The liver is divided into right and left anatomical lobes by the falciform ligament. Functionally, it is subdivided into eight segments, each supplied by a distinct branch of the portal triad. Part of the anatomical right lobe is thus functionally left-sided and referred to as the left medial section (segment IV), due to its supply by the branches of the left hepatic artery and portal vein. The dual vascular supply to the liver (75% portal vein, 25% hepatic artery) has important implications for intravenous contrast examinations and vascular intervention.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">HCC represents 85–90% of all primary hepatic malignancies. Morphologies in- clude solitary, multifocal, or diffusely infiltrating patterns. Local spread occurs via bile ducts and branches of the hepatic and portal veins, the latter acting as conduits for intrahepatic metastases. Extrahepatic spread occurs late, commonly to local lymph nodes, lungs, bone, and adrenal glands. HCC usually develops on the background of a cirrhotic liver, which can have typical morphological features such as atrophy, diffuse heterogeneity from fibrosis, or nodularity from regenerative nodules, in addition to</p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 9.1 <span class="s52">Typical imaging characteristics of benign lesions</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:14pt"><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Pathology</p></td><td style="width:172pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Typical imaging characteristics</p></td><td style="width:97pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Comment</p></td></tr><tr style="height:13pt"><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">simple cyst</p></td><td style="width:172pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">CT/Mri: thin-walled, well-defined, fluid-</p></td><td style="width:97pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Commonest lesion.</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">containing lesions. no internal septae or</p></td><td style="width:97pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">enhancement with contrast enhancement.</p></td><td style="width:97pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">us: anechoic with posterior acoustic</p></td><td style="width:97pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:54pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">enhancement.</p></td><td style="width:97pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">haemangioma</p></td><td style="width:172pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Well-defined, lobulated lesions. peripheral,</p></td><td style="width:97pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">second commonest</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">nodular, discontinuous enhancement with</p></td><td style="width:97pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lesion, more frequent in</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">progressive centripetal filling post-contrast.</p></td><td style="width:97pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">females, often multiple.</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">small lesions can show flash filling. large lesions</p></td><td style="width:97pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">may have a scar. enhancement follows vascular</p></td><td style="width:97pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:54pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">density at all phases.</p></td><td style="width:97pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Focal nodular</p></td><td style="width:172pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">hyper-enhancing, iso to mild T2 hyper-intensity.</p></td><td style="width:97pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">nineteen times</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">hyperplasia</p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">May have a T2 hyperintense central scar. often</p></td><td style="width:97pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">more common than</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">does retain liver specific contrast agent.</p></td><td style="width:97pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">adenoma. associated</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:97pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">with elevated circulating</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:97pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">oestrogen levels. More</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:97pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">common in women of</p></td></tr><tr style="height:13pt"><td style="width:54pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:97pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">childbearing age.</p></td></tr><tr style="height:13pt"><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">hepatic</p></td><td style="width:172pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">hyper-enhancing, mild T2 hyper-intensity, does</p></td><td style="width:97pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">More common in women</p></td></tr><tr style="height:11pt"><td style="width:54pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">adenoma</p></td><td style="width:172pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">not retain liver specific contrast agent. May</p></td><td style="width:97pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">of childbearing age.</p></td></tr><tr style="height:13pt"><td style="width:54pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">contain fat.</p></td><td style="width:97pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Focal fat</p></td><td style="width:172pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">no deviation of intrahepatic vessels or bile</p></td><td style="width:97pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:54pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">infiltration</p></td><td style="width:172pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">ducts. Diagnosed on ‘in and out of phase’ Mr</p></td><td style="width:97pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:172pt"><p class="s99" style="padding-left: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">sequences.</p></td><td style="width:97pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s54" style="padding-left: 5pt;text-indent: 0pt;line-height: 111%;text-align: left;">hepatic abscess</p><p class="s54" style="padding-left: 10pt;text-indent: -5pt;line-height: 111%;text-align: justify;">often in typical locations within the liver, for example adjacent to the falciform ligament.</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_126.png"/></span></p><p class="s54" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 111%;text-align: justify;">Variable appearance, often with mixed fluid/soft tissue attenuation. Can be difficult to distinguish from other lesions without aspiration/biopsy.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_127.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">evidence of associated portal hypertension such as splenomegaly, oesophageal varices, and ascites.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Early disease is typically identified on surveillance ultrasound (US) in the context of known cirrhosis (Figure 9.1), and frequency of imaging may depend on size or growth and vascular pattern of nodules. Advanced disease is more common in emergency or symptomatic presentations.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.2.1.2 <span class="s98">Non-invasive diagnosis</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Contrast-enhanced multiphasic computed tomography (CT) or magnetic resonance imaging (MRI) are gold standard first-line investigations in the diagnosis of primary liver cancers (Figure 9.2). The Liver Imaging-Reporting and Data System (LI-RADS) is widely adopted for the diagnosis of primary liver cancer in high-risk patients based on imaging alone. The ‘LR-M’ category comprises definitely or probably malignant</p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Table 9.2 <span class="s52">Typical imaging characteristics of metastatic lesions</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_128.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_129.png"/></span></p><p class="s39" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">US            CT/MRI            Comment</p><p class="s54" style="padding-top: 5pt;padding-left: 16pt;text-indent: -5pt;line-height: 111%;text-align: left;">Typically hypoechoic, ill-defined, irregular, rounded lesions +/- hypoechoic ring.</p><p class="s54" style="padding-left: 16pt;text-indent: -5pt;line-height: 111%;text-align: left;">us may help discriminate between small metastases versus simple cysts.</p><p class="s54" style="padding-top: 5pt;padding-left: 10pt;text-indent: -5pt;line-height: 111%;text-align: left;">CT: often ill-defined, low- attenuation in portal phase. sometimes ring enhancement (early phase) with washout (delayed phases).</p><p class="s54" style="padding-left: 10pt;text-indent: -5pt;line-height: 111%;text-align: left;">hypervascular metastases (e.g. neuroendocrine, renal, sarcoma, melanoma, occasionally colon/breast cancers): arterial enhancement followed by rapid washout, isodense/hypodense</p><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 111%;text-align: left;">to surrounding liver on portal phase (can be invisible on portal phase).</p><p class="s54" style="padding-left: 10pt;text-indent: -5pt;line-height: 111%;text-align: left;">Mri: typically low to intermediate signal (T1W), moderately high signal (T2W). enhancement characteristics as above. restrict diffusion. Do not retain liver specific contrast agents.</p><p class="s54" style="padding-top: 5pt;padding-left: 10pt;text-indent: -5pt;line-height: 111%;text-align: left;">Cystic metastases less common (ovary, colon, stomach), but cystic change in larger solid lesion or following chemotherapy not uncommon.</p><p class="s54" style="padding-left: 10pt;text-indent: -5pt;line-height: 111%;text-align: left;">Transcoelomic spread from ovarian cancer commonly cystic and found on peritoneal surface of liver.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_130.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">observations which are not specifically HCC, including atypical HCC, CCA, and mixed HCC-CCA where a confirmatory biopsy is needed. Features of LR-M lesions include a targetoid mass or infiltrative appearance, marked diffusion restriction, ne- crosis, or severe ischaemia. LI-RADS has been validated for high-risk (e.g. cirrhotic) patients only. The diagnostic hallmark of HCC on multiphasic CT/MRI consists of initial arterial phase hyperenhancement, followed by washout during portal venous or delayed phases. This phenomenon relies on the differential vascular supply of HCCs (hepatic artery) and surrounding benign liver (portal vein). In the context of existing cirrhosis, radiological hallmarks of HCC in nodules measuring 1 cm or greater indi- cate a high pre-test probability of HCC. This allows for radiological diagnosis in the absence of confirmatory biopsy, as risk of seeding and decompensation during the process is a concern for potentially curable disease. CT/MRI also have the ability to differentiate between thrombosis and malignant invasion of the portal vein, where the latter constitutes a key negative prognostic factor. Hepatobiliary-specific contrast agents, for example gadoxetate or gadobutrol, can be used in MR protocols to improve detection and characterization of lesions, such as focal nodular hyperplasia. Anatomic structure and function of the biliary tree can be delineated by evaluating biliary excre- tion of these agents.</p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.2.1.3 <span class="s98">Other imaging modalities</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">On US, HCC often appears hypoechoic, but appearances vary from hyperechoic to mixed. Contrast-enhanced US should not be used first line for radiological diag- nosis of HCC, as it cannot distinguish between intrahepatic CCA (iCCA) and HCC.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="7" height="6" alt="image" src="Image_131.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="7" height="81" alt="image" src="Image_132.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="21" height="7" alt="image" src="Image_133.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="339" height="410" alt="image" src="Image_134.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="21" height="7" alt="image" src="Image_135.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="33" height="7" alt="image" src="Image_136.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="28" height="27" alt="image" src="Image_137.png"/></span></p><p class="s14" style="text-indent: 0pt;text-align: left;">&lt;1cm</p><p class="s14" style="text-indent: 0pt;text-align: left;">&lt;1cm</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="text-indent: 0pt;text-align: left;">&lt;1cm</p><p class="s14" style="text-indent: 0pt;line-height: 106%;text-align: center;">Repeat abdominal ultrasound after 4 months</p><p class="s14" style="text-indent: 0pt;line-height: 106%;text-align: center;">Repeat abdominal ultrasound after 4 months</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="text-indent: 0pt;line-height: 106%;text-align: center;">Repeat abdominal ultrasound after 4 months</p><p class="s14" style="text-indent: 0pt;text-align: left;">Stable</p><p class="s14" style="text-indent: 0pt;text-align: left;">Stable</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="text-indent: 0pt;text-align: left;">Stable</p><p class="s14" style="text-indent: 0pt;text-align: left;">NO</p><p class="s14" style="text-indent: 0pt;text-align: left;">NO</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="text-indent: 0pt;text-align: left;">NO</p><p class="s14" style="text-indent: 0pt;line-height: 106%;text-align: left;">Uncertain histology: repeat biopsy if indicated</p><p class="s14" style="text-indent: 0pt;line-height: 106%;text-align: left;">Uncertain histology: repeat biopsy if indicated</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="text-indent: 0pt;line-height: 106%;text-align: left;">Uncertain histology: repeat biopsy if indicated</p><p class="s14" style="text-indent: 0pt;text-align: left;">HCC on Biopsy</p><p class="s14" style="text-indent: 0pt;text-align: left;">HCC on Biopsy</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="text-indent: 0pt;text-align: left;">HCC on Biopsy</p><p class="s14" style="text-indent: 0pt;text-align: left;">NO</p><p class="s14" style="text-indent: 0pt;text-align: left;">NO</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="text-indent: 0pt;text-align: left;">NO</p><p class="s14" style="padding-top: 3pt;padding-left: 6pt;text-indent: -4pt;line-height: 106%;text-align: left;">HCC hallmarks present on imaging technique two:</p><p class="s14" style="padding-top: 3pt;padding-left: 6pt;text-indent: -4pt;line-height: 106%;text-align: left;">HCC hallmarks present on imaging technique two:</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="padding-top: 3pt;padding-left: 6pt;text-indent: -4pt;line-height: 106%;text-align: left;">HCC hallmarks present on imaging technique two:</p><p class="s14" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">&gt;1cm</p><p class="s14" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">&gt;1cm</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">&gt;1cm</p><p class="s104" style="padding-top: 3pt;padding-left: 37pt;text-indent: 0pt;text-align: left;">Alternative diagnosis<span class="s14">:</span></p><p class="s14" style="padding-top: 4pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">• Benign disease</p><p class="s14" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">• Other primary hepatobiliary malignancy</p><p class="s14" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">• Metastatic disease from other primary</p><p class="s104" style="padding-top: 3pt;padding-left: 37pt;text-indent: 0pt;text-align: left;">Alternative diagnosis<span class="s14">:</span></p><p class="s14" style="padding-top: 4pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">• Benign disease</p><p class="s14" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">• Other primary hepatobiliary malignancy</p><p class="s14" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">• Metastatic disease from other primary</p><p style="text-indent: 0pt;text-align: left;"/><p class="s104" style="padding-top: 3pt;padding-left: 37pt;text-indent: 0pt;text-align: left;">Alternative diagnosis<span class="s14">:</span></p><p class="s14" style="padding-top: 4pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">• Benign disease</p><p class="s14" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">• Other primary hepatobiliary malignancy</p><p class="s14" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">• Metastatic disease from other primary</p><p class="s14" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;line-height: 106%;text-align: left;">Growing/ changing</p><p class="s14" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;line-height: 106%;text-align: left;">Growing/ changing</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="padding-top: 3pt;padding-left: 3pt;text-indent: 0pt;line-height: 106%;text-align: left;">Growing/ changing</p><p class="s14" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Mass or nodule on imaging</p><p class="s14" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Mass or nodule on imaging</p><p style="text-indent: 0pt;text-align: left;"/><p class="s14" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Mass or nodule on imaging</p><p style="text-indent: 0pt;text-align: left;"><span><img width="21" height="7" alt="image" src="Image_138.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s105" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">HCC</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s105" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">HCC</p><p style="text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s105" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">HCC</p><p style="text-indent: 0pt;text-align: left;"><span><img width="20" height="7" alt="image" src="Image_139.png"/></span></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:36pt"><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20" colspan="2"><p class="s106" style="padding-top: 4pt;padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 106%;text-align: center;">Proceed to multiphasic contrast-enhanced techniques (CT or MRI)</p></td></tr><tr style="height:26pt"><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:26pt"><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20" colspan="2"><p class="s106" style="padding-top: 3pt;padding-left: 6pt;text-indent: -3pt;line-height: 106%;text-align: left;">HCC hallmarks present on imaging technique one:</p></td></tr><tr style="height:20pt"><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20"><p class="s106" style="padding-top: 5pt;padding-left: 12pt;text-indent: 0pt;text-align: left;">NO</p></td></tr></table><table style="border-collapse:collapse" cellspacing="0"><tr style="height:36pt"><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20" colspan="2"><p class="s106" style="padding-top: 4pt;padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 106%;text-align: center;">Proceed to multiphasic contrast-enhanced techniques (CT or MRI)</p></td></tr><tr style="height:26pt"><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:26pt"><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20" colspan="2"><p class="s106" style="padding-top: 3pt;padding-left: 6pt;text-indent: -3pt;line-height: 106%;text-align: left;">HCC hallmarks present on imaging technique one:</p></td></tr><tr style="height:20pt"><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20"><p class="s106" style="padding-top: 5pt;padding-left: 12pt;text-indent: 0pt;text-align: left;">NO</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"/><table style="border-collapse:collapse" cellspacing="0"><tr style="height:36pt"><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20" colspan="2"><p class="s106" style="padding-top: 4pt;padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 106%;text-align: center;">Proceed to multiphasic contrast-enhanced techniques (CT or MRI)</p></td></tr><tr style="height:26pt"><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:26pt"><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20" colspan="2"><p class="s106" style="padding-top: 3pt;padding-left: 6pt;text-indent: -3pt;line-height: 106%;text-align: left;">HCC hallmarks present on imaging technique one:</p></td></tr><tr style="height:20pt"><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-right-style:solid;border-right-width:1pt;border-right-color:#231F20"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#231F20;border-left-style:solid;border-left-width:1pt;border-left-color:#231F20"><p class="s106" style="padding-top: 5pt;padding-left: 12pt;text-indent: 0pt;text-align: left;">NO</p></td></tr></table><p class="s14" style="padding-left: 11pt;text-indent: 0pt;text-align: right;">YES</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s14" style="padding-left: 11pt;text-indent: 0pt;text-align: right;">YES</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="21" height="7" alt="image" src="Image_140.png"/></span></p><p class="s14" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: right;">YES</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 9.1 <span class="s52">algorithm for investigation of nodules in cirrhosis.</span></p><p class="s107" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 119%;text-align: left;">adapted with permission from easl Clinical practice guidelines, ‘Management of hepatocellular carcinoma’. <i>J Hepatol. </i>Vol. 69, issue 1, pp.182–236. Copyright © 2018 elsevier.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Contrast enhanced US may, however, facilitate diagnosis of HCC where CT/MRI are contraindicated or inconclusive.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Positron emission tomography CT (PET/CT) is not used to diagnose HCC, as high false-negative rates have been observed, particularly in early/well-differentiated HCC. A role of PET-CT may include assessment of avidity as a marker of poor prognosis during patient selection for surgery.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.2.1.4 <span class="s98">Invasive diagnosis</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Biopsy, almost always guided by US, is required for tumours arising in non- cirrhotic livers, although histological confirmation, if safe and feasible, is</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="382" height="189" alt="image" src="Image_141.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 9.2 <span class="s52">(a) arterial phase axial T1 fat saturated Mr. There is a hyperenhancing mass in the left lateral section of the liver. (b) Delayed phase axial T1 fat saturated Mr. The mass demonstrates washout (the signal is now lower than the adjacent liver parenchyma) and a capsular enhancement pattern (the hyperintense ring surrounding the lesion). in the presence of cirrhosis and arterial phase hyperenhancement, these features are diagnostic of hepatocellular carcinoma.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">increasingly being required for all HCC patients to access systemic therapies in the advanced disease setting. This can facilitate differentiation of HCC from other hepatobiliary primaries, benign nodules, and metastatic disease from other sites. Immunohistochemical tests can provide further diagnostic certainty, particularly for poorly differentiated or mixed morphology tumours. Background tissue can also be taken to confirm presence of fibrosis or cirrhosis if this may influence sur- gical or ablative decisions.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.2.1.5 <span class="s98">Staging</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A multitude of HCC staging systems exist; however, the Barcelona Clinic Liver Cancer (BCLC) system is currently the most widely validated and implemented system. It integrates staging and treatment by stratifying patients into five groups (0, A–D), ac- cording to tumour size and multiplicity, vascular invasion, extrahepatic spread, liver function, and performance status (Table 9.3).</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.2.2 <span class="s29">Cholangiocarcinoma</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.2.2.1 <span class="s98">Background and anatomy</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">CCA represents 15–20% of primary hepatobiliary cancers. Macroscopic patterns in- clude mass-forming, periductal-infiltrating, and intraductal-papillary morpholo- gies. Divisions of the biliary tree inform subclassification of CCA into distal (dCCA), perihilar (pCCA), and iCCA. pCCA can be further classified anatomically into five types according to the Bismuth-Corlette system to inform surgical planning (Figure 9.3).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">iCCA (10–20%) often present non-specifically or incidentally, with a propen- sity for early intrahepatic metastasis. Extrahepatic CCA present with obstructive</p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 9.3 <span class="s52">hCC staging and management based on the modified BClC system</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:24pt"><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-right: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">Prognostic BCLC stage group</p></td><td style="width:59pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 112%;text-align: left;">Tumour characteristics</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 4pt;padding-right: 13pt;text-indent: 0pt;line-height: 112%;text-align: left;">Liver function</p></td><td style="width:26pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;padding-right: 3pt;text-indent: 0pt;line-height: 112%;text-align: left;">ECOG PS</p></td><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Treatment</p></td><td style="width:42pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 112%;text-align: left;">Treatment intent</p></td></tr><tr style="height:13pt"><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">0 Very early</p></td><td style="width:59pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">solitary nodule</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">preserved</p></td><td style="width:26pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">0</p></td><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">◆ <span class="s99">surgical resection, or</span></p></td><td style="width:42pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Curative</p></td></tr><tr style="height:11pt"><td style="width:61pt"><p class="s99" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">stage</p></td><td style="width:59pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">&lt;2 cm</p></td><td style="width:47pt"><p class="s99" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(i.e. Child-</p></td><td style="width:26pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:92pt"><p class="s88" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">◆ <span class="s99">ablative therapy (rFa).</span></p></td><td style="width:42pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:61pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:47pt"><p class="s99" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pugh a and</p></td><td style="width:26pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:92pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:42pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:61pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:47pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">no ascites)</p></td><td style="width:26pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:92pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:42pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">a early stage</p></td><td style="width:59pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">solitary nodule</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">preserved</p></td><td style="width:26pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">0</p></td><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">◆ <span class="s99">if optimal surgical</span></p></td><td style="width:42pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Curative</p></td></tr><tr style="height:11pt"><td style="width:61pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt"><p class="s99" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">&gt;2 cm</p></td><td style="width:47pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:26pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:92pt"><p class="s99" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">candidate, surgical</p></td><td style="width:42pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:61pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:47pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:26pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:92pt"><p class="s99" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">resection.</p></td><td style="width:42pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p class="s23" style="padding-left: 210pt;text-indent: -8pt;line-height: 109%;text-align: left;">◆ <span class="s54">if resection not possible, transplant if suitable candidate.</span></p><p class="s23" style="padding-bottom: 2pt;padding-left: 210pt;text-indent: -8pt;line-height: 109%;text-align: justify;">◆ <span class="s54">if candidate for neither, ablative therapy.</span></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:36pt"><td style="width:64pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">2–3 nodules</p><p class="s99" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">=&lt;3 cm</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">preserved</p></td><td style="width:24pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">0</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 14pt;padding-right: 9pt;text-indent: -8pt;line-height: 106%;text-align: left;">◆ <span class="s99">Transplant if suitable candidate.</span></p><p class="s88" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">◆ <span class="s99">if not, ablative therapy.</span></p></td><td style="width:42pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">Curative</p></td></tr><tr style="height:13pt"><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">B intermediate</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Multinodular,</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">preserved</p></td><td style="width:24pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">0</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 9pt;text-align: left;">◆ <span class="s99">Ta(C)e.</span></p></td><td style="width:42pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">palliative</p></td></tr><tr style="height:13pt"><td style="width:64pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 13pt;text-indent: 0pt;text-align: left;">stage</p></td><td style="width:56pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="text-indent: 0pt;text-align: left;">unresectable</p></td><td style="width:46pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:24pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:42pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">C advanced</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">portal invasion/</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">preserved</p></td><td style="width:24pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">1–2</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 9pt;text-align: left;">◆ <span class="s99">systemic therapy</span></p></td><td style="width:42pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">palliative</p></td></tr><tr style="height:11pt"><td style="width:64pt"><p class="s99" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">stage</p></td><td style="width:56pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">extrahepatic</p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt"><p class="s99" style="padding-left: 14pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(current first line:</p></td><td style="width:42pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt"><p class="s99" style="text-indent: 0pt;line-height: 9pt;text-align: left;">spread</p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt"><p class="s99" style="padding-left: 14pt;text-indent: 0pt;line-height: 9pt;text-align: left;">sorafenib/lenvatinib,</p></td><td style="width:42pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:64pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt"><p class="s99" style="padding-left: 14pt;text-indent: 0pt;line-height: 9pt;text-align: left;">regorafenib second</p></td><td style="width:42pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:64pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:24pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">line).</p></td><td style="width:42pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">D Terminal</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">hCC, non-</p></td><td style="width:46pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">end-stage</p></td><td style="width:24pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">3–4</p></td><td style="width:95pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s88" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;line-height: 9pt;text-align: left;">◆ <span class="s99">Best supportive care.</span></p></td><td style="width:42pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">palliative</p></td></tr><tr style="height:13pt"><td style="width:64pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 13pt;text-indent: 0pt;text-align: left;">stage</p></td><td style="width:56pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="text-indent: 0pt;text-align: left;">transplantable</p></td><td style="width:46pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">liver failure</p></td><td style="width:24pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:95pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:42pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">source: data from easl Clinical practice guidelines, ‘Management of hepatocellular carcinoma’. <i>J Hepatol.</i></p><p class="s14" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Vol. 69, issue 1, pp.182–236. elsevier 2018.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">complications, including jaundice and cholangitis, and are classified into pCCA (50–60%) and dCCA (20–30%). The latter require distinction from pancreatic, ampullary, or duodenal tumours, which is sometimes challenging.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.2.2.2 <span class="s98">Intrahepatic cholangiocarcinoma</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiological diagnosis of iCCA requires differentiation from HCC. The role of US is limited in this regard. Contrast-enhanced CT and MRI are the imaging modal- ities of choice, where CT is ideal for vascular assessment to determine resectability. Unlike HCC, iCCA typically demonstrate peripheral or rim enhancement on arterial phase, with subsequent central delayed phase enhancement. Biopsy is indicated if iCCA is suspected, as imaging appearances alone are not sufficient to make the diagnosis (there is an overlap with the appearances of metastases to the liver, Figure 9.4).</p><p style="text-indent: 0pt;text-align: left;"><span><img width="199" height="242" alt="image" src="Image_142.png"/></span></p><p class="s70" style="padding-top: 6pt;padding-left: 15pt;text-indent: 0pt;text-align: left;">HCC</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="36" height="66" alt="image" src="Image_143.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="38" height="66" alt="image" src="Image_144.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="38" height="66" alt="image" src="Image_145.png"/></span></p><p class="s70" style="padding-left: 11pt;text-indent: 0pt;text-align: right;">iCCA  <u>&nbsp; </u></p><p class="s70" style="padding-top: 5pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Bismuth - Corlette Classification</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s70" style="padding-left: 13pt;text-indent: 0pt;text-align: left;">GBC</p><p class="s70" style="padding-top: 5pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">pCCA</p><p class="s110" style="padding-top: 16pt;padding-left: 20pt;text-indent: 0pt;text-align: left;">TYPE I   <span class="s70">II    IIIa   </span><span class="s111">IIIb    </span><span class="s112">IV</span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="37" height="66" alt="image" src="Image_146.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="38" height="66" alt="image" src="Image_147.png"/></span></p><p class="s70" style="padding-top: 8pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">Extrahepatic CCA</p><p class="s70" style="padding-top: 15pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">dCCA</p><p class="s24" style="padding-top: 39pt;padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 9.3 <span class="s52">schematic of hepatobiliary anatomy. Tumours proximal to secondary branches of the right and left hepatic ducts constitute iCCa. pCCa are located at the right or left hepatic ducts or common bile duct cranial to the level of the cystic duct. dCCa are located inferior to this and cranial to the ampulla of Vater.</span></p><p class="s97" style="padding-top: 17pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.2.2.3 <span class="s98">Distal and perihilar cholangiocarcinoma</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">CT can accurately demonstrate vascular invasion and any anatomical anomalies, whilst MRCP is superior for assessing biliary involvement. The main differential diag- nosis for extrahepatic CCA includes benign strictures and IgG4 cholangiopathy.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="168" alt="image" src="Image_148.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 9.4 <span class="s52">(a) portal phase axial CT. There is a hypoenhancing mass in the right lobe of the liver. The lesion does not demonstrate any specific features, but appears malignant. The differential diagnosis for this lesion includes an intrahepatic cholangiocarcinoma and a metastasis.</span></p><p class="s52" style="padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: justify;">(b) oblique us. To confirm the nature of the lesion seen in 9.4a, a us guided biopsy has been carried out. The needle (arrows) is visible as a hyperechoic line, and the lesion (arrowheads) as a hypoechoic region. The biopsy confirmed intrahepatic cholangiocarcinoma.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="165" alt="image" src="Image_149.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 9.5 <span class="s52">(a) arterial phase coronal CT. inferior common duct cholangiocarcinoma, demonstrated as a hyperenhancing, shouldered stricture in the inferior common duct. Diagnosis is typically confirmed using eus-Fna. (b) Frontal fluoroscopic image. in this patient with perihilar cholangiocarcinoma, the tumour is visible as a stricture in the common hepatic duct (arrow). The tumour also involves the left hepatic duct and the confluence of the right anterior and right posterior hepatic ducts, in keeping with a Bismuth-Corlette type 3a lesion. external drains (arrowheads) are present in the</span></p><p class="s52" style="padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">right and left ductal systems, enabling the contrast medium to be injected to produce the image.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For pCCA (Figure 9.5), obtaining tissue in resectable cases is often impossible prior to resection. There is some concern regarding seeding, hence the use of endoscopic US fine needle aspiration (EUS FNA) in this context varies between centres. Endoscopic retrograde cholangiopancreatography (ERCP) brushings have a low sensitivity but are highly specific for both pCCA and dCCA. If ERCP brushings are negative, EUS FNA is used to make a preoperative diagnosis in dCCA. PTC (percutaneous transhepatic cholangiography) guided biopsy is, like ERCP brushings, specific but not sensitive. Both approaches may also allow for stent insertion.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.2.2.4 <span class="s98">Staging</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The majority of required staging information can be obtained from a multiphasic liver/ pancreas protocol CT with MRCP. Contrast enhanced liver MRI is also helpful to as- sess disease extent. PET-CT may have some value in assessing metastatic disease in select cases, but is not currently used routinely. iCCA, pCCA, and dCCA are staged according to separate criteria. Whilst the respective TNM AJCC/UICC systems are most widely applied, alternative systems are under development to better reflect prog- nostic outcomes.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.2.3 <span class="s29">Gallbladder carcinoma</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">This is uncommon and often associated with cholelithiasis. US typically shows a mass within or extending from the gallbladder or variable wall thickness. If resectable, tissue is not obtained prior to surgery.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 87pt;text-indent: 0pt;text-align: left;"><span><img width="223" height="271" alt="image" src="Image_150.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 9.6 <span class="s52">portal phase coronal CT. gall bladder cancer (arrows) is seen as a mass arising from the gall bladder.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The sensitivity of contrast-enhanced CT reportedly approaches 90%, and demon- strates a gallbladder mass or discontinuous gallbladder wall thickening (Figure 9.6). CT can also demonstrate direct hepatic spread, biliary tract dilatation, or vascular in- volvement, and is key to staging and identification of candidates for curative resection. MRI can further aid differentiation of malignant lesions from benign pathologies, including xanthogranulomatous cholecystitis.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.2.4 <span class="s29">Mixed hepatocellular cholangiocarcinoma</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Biphenotypic tumours (Figure 9.7) are a rare and poorly characterized entity, thought currently to represent less than 1% of primary hepatobiliary cancer diagnoses. Clinically, age of diagnosis and male preponderance reflect those of HCC, whereas poor survival figures resemble those of iCCA. Published data to date is sparse and in- sufficient to conclude on any definitive radiological hallmarks for mixed hepatocellular cholangiocarcinoma (HCC-CCA).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">9.3 <span class="h4">Therapeutic assessment and follow-up</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.3.1 <span class="s29">Overview</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">CT is the main radiological modality, with MRI or PET being used as problem-solving tools. Defined imaging protocols may be necessary to assess response to specific sur- gical or interventional management. For instance, a pre- and post-contrast CT is per- formed to assess for viable residual or recurrent disease following radiofrequency ablation (RFA) or transarterial (chemo)embolization (TA(C)E).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="167" alt="image" src="Image_151.gif"/></span></p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 9.7 <span class="s52">arterial phase coronal CT. Biphenotypic tumours share imaging features with both hepatocellular carcinoma and intrahepatic cholangiocarcinoma. in this case, arterial hyperenhancement is present (arrows), as well as tumour thrombus in the right portal vein (arrowheads).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.3.2 <span class="s29">Ablative techniques</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Percutaneous ablative therapies act by causing coagulative tumour necrosis, using thermal techniques (including RFA, microwave ablation, laser ablation, and cryoablation) or chemical injection of ethanol (PEI) or acetic acid. RFA is a standard first-line treatment option in stage BCLC 0 or A HCC when deemed unsuitable for sur- gery, with the same overall survival outcomes compared to surgical resection in lesions measuring less than 2 cm. US or CT are used for image guidance (Figure 9.8), and image fusion may improve procedure accuracy, particularly for ill-defined lesions on US.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.3.3 <span class="s29">Transarterial (chemo)embolization</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">(TA(C)E is an established standard of care in BCLC stage B (asymptomatic large or multinodular) HCC, with an established overall survival advantage in HCC. Altered</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="167" alt="image" src="Image_152.jpg"/></span></p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 9.8 <span class="s52">oblique us. us can be used to guide radiofrequency ablation for the treatment of hCC. The needle is visible as an echogenic line (arrows) and the ablation zone as an echogenic region surrounding it.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="259" alt="image" src="Image_153.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 9.9 <span class="s52">arterial phase frontal fluoroscopic image. hCC can be treated using transarterial embolization. in this case a catheter has been inserted into the hepatic artery to allow the injection of embolic material.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">portal venous circulation, deteriorating performance status, hepatic decompensation, biliary stenting, biliary-enteric anastomoses, and segmental portal vein invasion are known factors associated with poor outcomes. With good patient selection, median survival figures are in the region of 40–50 months.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Embolization of the tumour feeding artery (Figure 9.9) uses embolizing agents such as polyvinyl alcohol or gelfoam, and may involve, in addition, direct delivery of an anthracycline or platinum-based cytotoxic agent followed by occlusion of the tumour vascular supply to cause tumour ischaemia and infarction. Drug eluting beads can also be used in the procedure. Treatment response is assessed with contrast-enhanced CT or MRI at four weeks post-treatment and the change in viable tumour bulk is evaluated (see section 9.3.6).</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9.3.4 <span class="s29">Selective internal radiation therapy</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">SIRT, also referred to as transarterial radioembolization (TARE), is image-guided brachytherapy using beta-radiation from Yttrium-90 microspheres and subsequent ischaemia through arterial embolization to mediate a cytotoxic effect. Planning angi- ography is undertaken pre-treatment, including prophylactic embolization of non- target arteries and identification of any anatomical variants. SPECT scanning with the radiotracer 99mTc-macroaggregated albumin (MAA) is performed to ensure safe levels of hepatopulmonary shunting prior to SIRT (Figure 9.10).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Although SIRT has been used for solitary HCC lesions too large for, refractory to, or anatomically unlikely to respond to TA(C)E, with objective response rates between</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="415" height="295" alt="image" src="Image_154.gif"/></span></p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s70" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 9.10 <span class="s52">(a) During sirT work-up the presence of collateral shunts from hepatic vessels (common hepatic artery (Cha), left hepatic artery (lha), right hepatic artery (rha)) which can affect distribution of radioactive microspheres is established by angiography. angiography here shows three lesions by the presence of focal contrast accumulation as a ‘tumour blush’. (b) 99 mTc Maa, which is a similar size to the treatment microspheres, is injected, and distribution assessed here using a speCT scan to calculate lung shunts by</span></p><p class="s52" style="padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">evaluating uptake in liver and lung versus liver alone. radiation exposure is considered too high if lung shunt value is over 10%. (c) speCT scan of liver shows good distribution of activity in both lobes with uptake around the tumour and no extra-hepatic uptake.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">35–50%, published evidence of overall survival advantage, particularly in BCLC C dis- ease, is lacking to date.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.3.5 <span class="s29">Radiotherapy</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Clinical trials are exploring the safety and efficacy of external beam radiotherapy tech- niques including IMRT (intensity-modulated radiotherapy) and SBRT (stereotactic body radiation therapy) for hepatobiliary cancers, for instance in resected CCA or unresectable iCCA. However, the role of radiotherapy for these tumours is yet to be established, and is largely performed within a research setting at present.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.3.6 <span class="s29">Systemic therapies</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">For advanced cholangiocarcinomas and gallbladder cancers, gemcitabine and cis- platin have been established as a standard of care treatment. For efficacy of cytotoxic treatment in solid cancers, tumour response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria is frequently used as a surrogate for survival outcomes.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">However, use of anatomic tumour response parameters, such as change in sum of maximal diameters of lesions, can be ambiguous when evaluating the loco-regional therapies of the molecularly targeted agents (MTAs) or anti-angiogenic therapies used in management of advanced HCC. These now include the multi-targeted tyro- sine kinase inhibitors sorafenib (VEGFR, PDGFR, Raf family), lenvatinib (VEGFR1-3, FGFR1-4) in the first-line treatment setting, and in the second-line setting regorafenib (VEGFR2, TIE2, FGFR1), cabozantinib (VEGFR, AXL, MET), and the anti-angiogenic monoclonal antibody against VEGFR2, ramucirumab.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">RECIST criteria have, therefore, been amended to encompass the notion of viable tumoural tissue showing uptake in the arterial phase of contrast-enhanced imaging techniques, the modified RECIST (mRECIST). Reports suggesting activity from the immune checkpoint PD-1 inhibitors, nivolumab and pembrolizumab as monotherapy or in combination with MTAs in advanced HCC means that immune-related response criteria may also become incorporated into the response assessments for this tumour in the future.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">9.4 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Dynamic contrast-enhanced CT and MRI form the basis of radiological diagnosis and surgical planning.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">HCC often arises in the background of abnormal cirrhotic liver and demonstrates typical features, which have previously permitted diagnosis in the absence of histo- logical confirmation on non-invasive criteria.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">It may not be possible to acquire tissue from pCCA or gallbladder cancer prior to resection—alternative diagnoses are excluded and then confirmation of malig- nancy is only possible after surgical removal.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Modified RECIST criteria have been developed to address the concept of viable tumour following treatment of HCC with loco-regional therapies or MTAs within response assessments, although these require validation.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Further reading</p><p class="s74" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><b>Blechacz B </b>(2017). Cholangiocarcinoma: current knowledge and new developments. <i>Gut Liver</i>,</p><p class="s75" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">11<span class="s74">(1): 13–26.</span></p><p class="s75" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;">Chernyak V, Fowler KJ, Kamaya A, et al. <span class="s74">(2018). Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients.</span></p><p class="s74" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><i>Radiology</i>, <b>289</b>, 816–830.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><b>Chow PKH</b>, <b>Gandhi M</b>, <b>Tan SB, et al. </b>(2018). SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. <i>Journal of Clinical Oncology</i>, <b>36</b>(19): 1913–1921.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: justify;"><b>European Association for the Study of the Liver </b>(2018). EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. <i>Journal of Hepatology</i>, <b>69</b>(1): 182–236.</p><p class="s74" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: justify;"><b>Forner A</b>, <b>Reig M</b>, <b>Bruix J </b>(2018). Hepatocellular carcinoma. <i>Lancet</i>, <b>391</b>(10127): 1301–1314.</p><p class="s74" style="padding-top: 4pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Hennedige TP</b>, <b>Neo WT</b>, <b>Venkatesh SK </b>(2014). Imaging of malignancies of the biliary tract— an update. <i>Cancer Imaging</i>, <b>14</b>: 14.</p><p class="s75" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Lencioni R<span class="s74">, </span>Petruzzi P<span class="s74">, </span>Crocetti L <span class="s74">(2013). Chemoembolization of hepatocellular carcinoma.</span></p><p class="s74" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><i>Seminars in Interventional Radiology</i>, <b>30</b>(1): 3–11.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>McEvoy SH</b>, <b>McCarthy CJ</b>, <b>Lavelle LP, et al. </b>(2013). Hepatocellular carcinoma: illustrated guide to systematic radiologic diagnosis and staging according to guidelines of the American Association for the Study of Liver Diseases. <i>Radiographics</i>, <b>33</b>(6): 1653–1168.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Roberts LR</b>, <b>Sirlin CB</b>, <b>Zaiem F, et al. </b>(2018). Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. <i>Hepatology</i>, <b>67</b>(1): 401–421.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Wang EA</b>, <b>Broadwell SR</b>, <b>Bellavia RJ</b>, <b>Stein JP (2017)</b>. Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma. <i>Journal of Gastrointestinal Oncology</i>, <b>8</b>(2): 266–278.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part14.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part16.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
